التداخل بين ميثيل فينيدات وراساجيلين

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ].

Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days.

Intervention Do not administer methylphenidate extended-release orally disintegrating tablets concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment.

Clinically Important Interactions with Methylphenidate Extended-Release Orally Disintegrating Tablets Table 1: Drugs Having Clinically Important Interactions with Methylphenidate Monoamine Oxidase Inhibitors (MAOI) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis.

Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline and sympathomimetic medications.

Severe hypertension has been reported in patients taking the recommended dose of rasagiline and ophthalmic drops containing sympathomimetic medications.

Nevertheless, caution should be exercised when concomitantly using recommended doses of rasagiline with any sympathomimetic medications including nasal, oral, and ophthalmic decongestants and cold remedies.

Sympathomimetic Medications The concomitant use of rasagiline and sympathomimetic medications was not allowed in clinical studies.

Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors.